Kura Research Development from 2010 to 2026
| KURA Stock | USD 8.12 0.10 1.22% |
Research Development | First Reported 2014-09-30 | Previous Quarter 62.8 M | Current Value 67.9 M | Quarterly Volatility 16.4 M |
Check Kura Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kura Oncology's main balance sheet or income statement drivers, such as Other Operating Expenses of 298.3 M, Total Operating Expenses of 298.3 M or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 11.14, Dividend Yield of 0.0 or PTB Ratio of 1.98. Kura financial statements analysis is a perfect complement when working with Kura Oncology Valuation or Volatility modules.
Kura | Research Development | Build AI portfolio with Kura Stock |
Analyzing Kura Oncology's Research Development over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Research Development has evolved provides context for assessing Kura Oncology's current valuation and future prospects.
Latest Kura Oncology's Research Development Growth Pattern
Below is the plot of the Research Development of Kura Oncology over the last few years. It is Kura Oncology's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kura Oncology's overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Kura Research Development Regression Statistics
| Arithmetic Mean | 66,075,247 | |
| Geometric Mean | 35,873,571 | |
| Coefficient Of Variation | 102.89 | |
| Mean Deviation | 54,938,908 | |
| Median | 46,787,000 | |
| Standard Deviation | 67,981,637 | |
| Sample Variance | 4621.5T | |
| Range | 197.2M | |
| R-Value | 0.92 | |
| Mean Square Error | 782T | |
| R-Squared | 0.84 | |
| Slope | 12,348,477 | |
| Total Sum of Squares | 73944T |
Kura Research Development History
About Kura Oncology Financial Statements
Kura Oncology stakeholders use historical fundamental indicators, such as Kura Oncology's Research Development, to determine how well the company is positioned to perform in the future. Although Kura Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kura Oncology's assets and liabilities are reflected in the revenues and expenses on Kura Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kura Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 195.5 M | 205.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out the analysis of Kura Oncology Correlation against competitors. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. Expected growth trajectory for Kura significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kura Oncology assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Kura Oncology requires distinguishing between market price and book value, where the latter reflects Kura's accounting equity. The concept of intrinsic value—what Kura Oncology's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Kura Oncology's price substantially above or below its fundamental value.
Understanding that Kura Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kura Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Kura Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.